Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer

This study is ongoing, but not recruiting participants.

Sponsored by:	King Faisal Specialist Hospital & Research Center
Information provided by:	King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:	NCT00538395

Purpose

Intensive sequential chemotherapy with Adriamycin Taxol and Cytoxan in the treatment of locally advanced breast cancer

Condition	Intervention
Breast Cancer	Drug: Adriamycin, Taxol and Cytoxan

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

Drug Information available for: Doxorubicin Doxorubicin hydrochloride Cyclophosphamide Paclitaxel

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Open Label, Single Group Assignment

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Patients with locally advanced breast cancer

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00538395

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators

Principal Investigator:

Adnan Ezzat, MD

KFSH&RC, Riyadh, Saudi Arabia

More Information

Study ID Numbers:	RAC #981-020
Study First Received:	October 1, 2007
Last Updated:	October 1, 2007
ClinicalTrials.gov Identifier:	NCT00538395
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Skin Diseases
Paclitaxel
Breast Neoplasms

Cyclophosphamide
Doxorubicin
Breast Diseases

Additional relevant MeSH terms:

Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Immunosuppressive Agents
Pharmacologic Actions

Neoplasms
Neoplasms by Site
Therapeutic Uses
Myeloablative Agonists
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Alkylating Agents

ClinicalTrials.gov processed this record on January 16, 2009